Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gut microbiota is a complex community of microorganisms residing in the digestive tract, primarily composed of bacteria. These bacteria play crucial roles in digestion, vitamin synthesis, immune modulation, and protection against pathogens. Some bacteria produce toxins, such as lipopolysaccharides (LPS), which can trigger inflammation. Dysbiosis, or disruption of the gut microbiota, can lead to various diseases including obesity, diabetes, inflammatory bowel disease, and increased cancer risk. Interventions like antibiotics, prebiotics, probiotics, and fecal microbiota transplantation (FMT) can impact the gut microbiota composition and function.
Variable, depends on specific bacteria, toxin, or treatment. Antibiotics kill bacteria, prebiotics promote growth of beneficial bacteria, probiotics introduce beneficial bacteria, FMT replaces the entire gut microbiota.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut Microbiota and Bacterial Toxins.